AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + laser
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + Sn + MB + laser
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + MB + laser
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + Sn
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + Sn + laser
Number of subjects: 8
Study 25768712 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy health education group (90 subjects) received a structured educational program consisting of 4 sessions.
Number of subjects: 180
Study 25768712 — intervention group
Group type: COMPARATOR
Intervention: Control group (90 subjects) received standard of care without structured educational program.
Number of subjects: 180
Study 25768712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Epilepsy health education and Control) assessed using ESES scores.
Number of subjects: 180
Study 24829961 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 19
Study 24829961 — intervention group
Group type: COMPARATOR
Intervention: Sham-tape
Number of subjects: 19
Study 21949034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Platelet Volume (MPV)
Number of subjects: 203
Study 21949034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Platelet Mass (MPM)
Number of subjects: 203
Study 21949034 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Platelet Component (MPC)
Number of subjects: 203
Study 21949034 — intervention group
Group type: COMPARATOR
Intervention: Platelet activity indices (MPV, MPM, MPC)
Number of subjects: 203
Study 19625978 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 477
Study 19625978 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists (clonidine and guanfacine)
Number of subjects: 477
Study 19625978 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 477
Study 19625978 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 477
Study 19625978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (supratherapeutic doses)
Number of subjects: 477
Study 19625978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 17519409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 767
Study 17519409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 767
Study 17519409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 767
Study 17519409 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine and sulfadoxine-pyrimethamine
Number of subjects: 767
Study 15165648 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Focused Grief Therapy (FFGT)
Number of subjects: 81
Study 11419830 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted educational session (group 1)
Number of subjects: 142
Study 11419830 — intervention group
Group type: COMPARATOR
Intervention: No educational session (group 2)
Number of subjects: 142
Study 11419830 — intervention group
Group type: COMPARATOR
Intervention: Telephonic instruction (group 3)
Number of subjects: 142
Study 11419830 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 142
Study 11419830 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 142
Study 9735523 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention implemented by regular staff
Number of subjects: 0
Study 9735523 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (no specific intervention mentioned)
Number of subjects: 0
Study 7981389 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration chemotherapy
Number of subjects: 0
Study 7981389 — intervention group
Group type: COMPARATOR
Intervention: Long-duration chemotherapy
Number of subjects: 0
Study 2662740 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC treatment
Number of subjects: 1004
Study 2662740 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 1004
Study 236337 — intervention group
Group type: EXPERIMENTAL
Intervention: pipradrol‐vitamin (Alertonic) elixir
Number of subjects: 99
Study 236337 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study 236337 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 99
Study 31145308 — intervention group
Group type: EXPERIMENTAL
Intervention: rhACE2
Number of subjects: 0
Study 31145308 — intervention group
Group type: COMPARATOR
Intervention: Ang II
Number of subjects: 0
Study 31145308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29231341 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 29
Study 29231341 — intervention group
Group type: COMPARATOR
Intervention: Diane-35 (western medication)
Number of subjects: 29
Study 25331845 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral baroreflex activation therapy (BAT)
Number of subjects: 295
Study 25331845 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided stimulation
Number of subjects: 295
Study 25331845 — intervention group
Group type: COMPARATOR
Intervention: Bilateral baroreflex activation therapy (BAT)
Number of subjects: 295
Study 24021393 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including health ambassador, study circle for caregivers, and health course for residents, lasting 12-16 months.
Number of subjects: 130
Study 24021393 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 130
Study 21471085 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (5 mg twice daily)
Number of subjects: 66
Study 21471085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17418218 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg daily for 28 days
Number of subjects: 507
Study 17418218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 15795006 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive augmented information feedback
Number of subjects: 0
Study 15795006 — intervention group
Group type: COMPARATOR
Intervention: No augmented information feedback
Number of subjects: 0
Study 12559860 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 50 microg/kg
Number of subjects: 40
Study 12559860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10751379 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Safe in the Sun' curriculum programme
Number of subjects: 11
Study 10751379 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers using materials as recommended
Number of subjects: 11
Study 10751379 — intervention group
Group type: EXPERIMENTAL
Intervention: All levels of intervention
Number of subjects: 11
Study 8785139 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil‐nitrous oxide‐oxygen‐isoflurane (n = 10)
Number of subjects: 90
Study 8785139 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil‐nitrous oxide‐oxygen‐sevoflurane (n = 10)
Number of subjects: 90
Study 8785139 — intervention group
Group type: COMPARATOR
Intervention: alfentanil‐nitrous oxide‐oxygen (n = 10)
Number of subjects: 90
Study 1494924 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.2-cm catheter
Number of subjects: 89
Study 1494924 — intervention group
Group type: COMPARATOR
Intervention: 4.45-cm catheter
Number of subjects: 89
Study 6466255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg daily
Number of subjects: 9
Study 6466255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31464859 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term follow-up (0-27 months)
Number of subjects: 534
Study 31464859 — intervention group
Group type: EXPERIMENTAL
Intervention: Having 2 or more lifetime sex partners
Number of subjects: 534
Study 31464859 — intervention group
Group type: EXPERIMENTAL
Intervention: History of any sexually transmitted disease
Number of subjects: 534
Study 31464859 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire follow-up (0-76 months)
Number of subjects: 534
Study 31464859 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of lifetime partners
Number of subjects: 534
Study 30259644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 1025
Study 30259644 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal faster aspart
Number of subjects: 1025
Study 30259644 — intervention group
Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 1025
Study 25924097 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of video of themselves in pain
Number of subjects: 30
Study 25924097 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of video of spouse in pain
Number of subjects: 30
Study 25924097 — intervention group
Group type: COMPARATOR
Intervention: Lukewarm water immersion without empathic observation
Number of subjects: 30
Study 25317091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 250 mg
Number of subjects: 256
Study 25317091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 22331056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg tid for 6 weeks)
Number of subjects: 27
Study 22331056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20819324 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4000 mg/day)
Number of subjects: 30
Study 20819324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20819324 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 30
Study 20819324 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 30
Study 17460335 — intervention group
Group type: EXPERIMENTAL
Intervention: Novedex XT
Number of subjects: 16
Study 17460335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12804077 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g of aromatics inunction
Number of subjects: 12
Study 12804077 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum placebo
Number of subjects: 12
Study 12804077 — intervention group
Group type: COMPARATOR
Intervention: No-treatment baseline
Number of subjects: 12
Study 11112238 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 30 mg
Number of subjects: 1145
Study 11112238 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 1145
Study 11112238 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 1145
Study 11112238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study 11112238 — intervention group
Group type: EXPERIMENTAL
Intervention: All Raloxifene groups
Number of subjects: 1145
Study 11112238 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1145
Study 9364981 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of antiprothrombin antibodies
Number of subjects: 530
Study 9364981 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls with no thromboembolic events)
Number of subjects: 530
Study 7968334 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Airway Suctioning (CAS)
Number of subjects: 16
Study 7968334 — intervention group
Group type: COMPARATOR
Intervention: Standard Suctioning (SS)
Number of subjects: 16
Study 2872059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol 400 mg
Number of subjects: 7
Study 2872059 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 7
Study 2872059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29777404 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional treatment (LRT)
Number of subjects: 274
Study 29777404 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST)
Number of subjects: 274
Study 26945315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue preservation
Number of subjects: 25
Study 24833235 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 14264
Study 24833235 — intervention group
Group type: EXPERIMENTAL
Intervention: Other AADs
Number of subjects: 14264
Study 24833235 — intervention group
Group type: COMPARATOR
Intervention: Warfarin with Amiodarone
Number of subjects: 14264
Study 24833235 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban vs Warfarin (no AAD)
Number of subjects: 14264
Study 22569564 — intervention group
Group type: EXPERIMENTAL
Intervention: ITN protection from birth
Number of subjects: 120
Study 22569564 — intervention group
Group type: COMPARATOR
Intervention: ITN protection from month six onwards
Number of subjects: 120
Study 20194359 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with a quit date
Number of subjects: 283
Study 20194359 — intervention group
Group type: COMPARATOR
Intervention: Smokers without a quit date
Number of subjects: 283
Study 17891382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopamine D2 agonist)
Number of subjects: 0
Study 17891382 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (dopamine D2 antagonist)
Number of subjects: 0
Study 17891382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15953423 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0
Study 12701826 — intervention group
Group type: COMPARATOR
Intervention: Cr‐mH (0.125 g/kg/day)
Number of subjects: 57
Study 12701826 — intervention group
Group type: COMPARATOR
Intervention: Cr‐mH (0.075 g/kg/day)
Number of subjects: 57
Study 12701826 — intervention group
Group type: COMPARATOR
Intervention: Cr‐mH (mean = 0.18 g/kg/day)
Number of subjects: 57
Study 12701826 — intervention group
Group type: COMPARATOR
Intervention: Weight training in young men
Number of subjects: 57
Study 12701826 — intervention group
Group type: COMPARATOR
Intervention: Weight training in elderly subjects
Number of subjects: 57
Study 10483801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.21 liters of water (W)
Number of subjects: 6
Study 10483801 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (S) containing 100 mmol of NaCl x l(‐1)
Number of subjects: 6
Study 10483801 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 6
Study 8709370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical capsaicin (10 microM, twice weekly for 1 month)
Number of subjects: 36
Study 8709370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1897307 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg Pasteur BCG by intradermal injection
Number of subjects: 291
Study 1897307 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg Pasteur BCG by intradermal injection
Number of subjects: 291
Study 7160389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Coronary Care Unit (MCCU)
Number of subjects: 821
Study 7160389 — intervention group
Group type: COMPARATOR
Intervention: Standard Ambulance (STA)
Number of subjects: 821
Study 31246370 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT group (n = 22)
Number of subjects: 65
Study 31246370 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT group (n = 20)
Number of subjects: 65
Study 31246370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACT + DBT + FAP therapy group (n = 23)
Number of subjects: 65
Study 31246370 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 65
Study 31465494 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-citizens (n = 369)
Number of subjects: 57556
Study 31465494 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-citizens (n = 2,463)
Number of subjects: 57556
Study 31465494 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-citizens with knowledge of HIV-positive status (n = 72)
Number of subjects: 57556
Study 27798754 — intervention group
Group type: EXPERIMENTAL
Intervention: To-be-ignored auditory distractor words from different categories
Number of subjects: 0
Study 27798754 — intervention group
Group type: COMPARATOR
Intervention: Quiet control condition
Number of subjects: 0
Study 25811947 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel-depth heavy squat-lift training (HS-P)
Number of subjects: 36
Study 25811947 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel-depth jump squat training (JS-P)
Number of subjects: 36
Study 25811947 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional-depth jump squat training (JS-V)
Number of subjects: 36
Study 25811947 — intervention group
Group type: COMPARATOR
Intervention: No training (C)
Number of subjects: 36
Study 24478107 — intervention group
Group type: EXPERIMENTAL
Intervention: RS4-enriched flour (30% v/v)
Number of subjects: 86
Study 21761712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up group A (79 patients)
Number of subjects: 132
Study 21761712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up group B (28 patients)
Number of subjects: 132
Study 21761712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up group C (24 patients)
Number of subjects: 132
Study 21761712 — intervention group
Group type: COMPARATOR
Intervention: Control group (53 patients)
Number of subjects: 132
Study 19094161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 24
Study 19094161 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 5 mg (active control)
Number of subjects: 24
Study 19094161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17349881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500 to 1,000 mg twice daily)
Number of subjects: 746
Study 17349881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 746
Study 15313288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged silicone intraocular lens (ClariFlex OptiEdge)
Number of subjects: 52
Study 15313288 — intervention group
Group type: COMPARATOR
Intervention: Round-edged silicone intraocular lens (PhacoFlex SI-40)
Number of subjects: 52
Study 11759135 — intervention group
Group type: EXPERIMENTAL
Intervention: Word associations presented via headphones during anesthesia (Trivial Pursuit game statements)
Number of subjects: 48
Study 11759135 — intervention group
Group type: COMPARATOR
Intervention: Control word associations (not specified in detail)
Number of subjects: 48
Study 9251634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (sulphasalazine 2 g/day, methotrexate 7.5 mg/week, prednisolone initially 60 mg/day tapered to 7.5 mg/day)
Number of subjects: 155
Study 9251634 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine alone
Number of subjects: 155
Study 9251634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 155
Study 8329251 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 35
Study 8329251 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35
Study 8329251 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Propofol
Number of subjects: 35
Study 3574695 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 3574695 — intervention group
Group type: COMPARATOR
Intervention: ECT
Number of subjects: 0
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmatic non-pharmacological support
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to quit
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational education
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: High school education
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 2904
Study 29431134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases
Number of subjects: 2904
Study 27236335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent programme for integrated management of chronic musculoskeletal pain and depression
Number of subjects: 330
Study 27236335 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study 24464791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin/Chlorhexidine (M/C)
Number of subjects: 515
Study 24464791 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin/Tobramycin (P/T)
Number of subjects: 515
Study 22369393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus (510 mg/day for a median of 4.0 days)
Number of subjects: 304
Study 22369393 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed group (control)
Number of subjects: 304
Study 22369393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Number of subjects: 304
Study 20666950 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline during bipolar resectoscopy
Number of subjects: 155
Study 20666950 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glycine during monopolar resectoscopy
Number of subjects: 155
Study 18729669 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 156
Study 18729669 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 156
Study 16192835 — intervention group
Group type: EXPERIMENTAL
Intervention: LY354740 (100 or 200 mg)
Number of subjects: 0
Study 16192835 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (60 mg)
Number of subjects: 0
Study 16192835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12007950 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy in 3 fractions on alternate days (6 Gy per fraction, Group A)
Number of subjects: 232